Bromodomains: a new target class for drug development

AG Cochran, AR Conery, RJ Sims III - Nature Reviews Drug Discovery, 2019 - nature.com
Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader'modules
found in proteins with varied functions, were highly tractable small-molecule targets. This is …

The BET family in immunity and disease

N Wang, R Wu, D Tang, R Kang - Signal transduction and targeted …, 2021 - nature.com
Innate immunity serves as the rapid and first-line defense against invading pathogens, and
this process can be regulated at various levels, including epigenetic mechanisms. The …

Bromodomain and extraterminal proteins as novel epigenetic targets for renal diseases

JL Morgado-Pascual, S Rayego-Mateos… - Frontiers in …, 2019 - frontiersin.org
Epigenetic mechanisms, especially DNA methylation and histone modifications, are
dynamic processes that regulate the gene expression transcriptional program in normal and …

Targeting bromodomain-selective inhibitors of BET proteins in drug discovery and development

J Chen, P Tang, Y Wang, J Wang, C Yang… - Journal of medicinal …, 2022 - ACS Publications
Blocking the interactions between bromodomain and extraterminal (BET) proteins and
acetylated lysines of histones by small molecules has important implications for the …

Discovery of tetrahydroquinoxalines as bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the second bromodomain

RP Law, SJ Atkinson, P Bamborough… - Journal of Medicinal …, 2018 - ACS Publications
The bromodomain and extra-terminal domain (BET) family of proteins bind acetylated lysine
residues on histone proteins. The four BET bromodomains—BRD2, BRD3, BRD4, and …

The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) …

JT Seal, SJ Atkinson, H Aylott… - Journal of Medicinal …, 2020 - ACS Publications
The profound efficacy, yet associated toxicity of pan-BET inhibitors is well documented. The
possibility of an ameliorated safety profile driven by significantly selective (> 100-fold) …

Therapeutic epigenetic reprogramming of trained immunity in myeloid cells

RM Rodriguez, B Suarez-Alvarez, C Lopez-Larrea - Trends in Immunology, 2019 - cell.com
Infiltrating and tissue-resident myeloid cells are essential regulators of innate and adaptive
immunity. During inflammation, and in response to microbial products, these cells can adapt …

Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of …

Z Wang, L Yin, Z Xiong, F Huang, N Yang… - Journal of Medicinal …, 2023 - ACS Publications
Selective inhibitors targeting the first bromodomain (BD1) or the second bromodomain
(BD2) of the bromodomain and extra terminal domain (BET) proteins have triggered …

Selective and cell-active PBRM1 bromodomain inhibitors discovered through NMR fragment screening

S Shishodia, R Nuñez, BP Strohmier… - Journal of medicinal …, 2022 - ACS Publications
PBRM1 is a subunit of the PBAF chromatin remodeling complex that uniquely contains six
bromodomains. PBRM1 can operate as a tumor suppressor or tumor promoter. PBRM1 is a …

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of …

A Preston, S Atkinson, P Bamborough… - Journal of Medicinal …, 2020 - ACS Publications
Pan-bromodomain and extra terminal domain (BET) inhibitors interact equipotently with the
eight bromodomains of the BET family of proteins and have shown profound efficacy in a …